12,655 Shares in Kiniksa Pharmaceuticals International, plc $KNSA Purchased by PSP Research LLC

PSP Research LLC bought a new position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 12,655 shares of the company’s stock, valued at approximately $522,000.

Several other large investors also recently modified their holdings of the business. HighTower Advisors LLC bought a new stake in Kiniksa Pharmaceuticals International during the 4th quarter valued at approximately $360,000. Swiss Life Asset Management Ltd bought a new stake in Kiniksa Pharmaceuticals International during the 4th quarter valued at approximately $202,000. Kornitzer Capital Management Inc. KS bought a new stake in Kiniksa Pharmaceuticals International during the 4th quarter valued at approximately $911,000. State of New Jersey Common Pension Fund D bought a new stake in Kiniksa Pharmaceuticals International during the 4th quarter valued at approximately $490,000. Finally, UBS Group AG boosted its position in Kiniksa Pharmaceuticals International by 56.4% during the 4th quarter. UBS Group AG now owns 77,916 shares of the company’s stock valued at $3,214,000 after acquiring an additional 28,099 shares in the last quarter. 53.95% of the stock is owned by institutional investors.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, CAO Michael R. Megna sold 6,625 shares of the company’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $46.69, for a total value of $309,321.25. Following the completion of the transaction, the chief accounting officer owned 27,418 shares of the company’s stock, valued at approximately $1,280,146.42. This represents a 19.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 48,565 shares of the company’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $54.02, for a total transaction of $2,623,481.30. Following the completion of the transaction, the chief executive officer directly owned 48,565 shares of the company’s stock, valued at $2,623,481.30. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 653,301 shares of company stock worth $34,046,073. 51.98% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Jefferies Financial Group lifted their price objective on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Wells Fargo & Company boosted their price target on Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 29th. Wedbush boosted their price target on Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 29th. Citigroup boosted their price target on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Finally, Weiss Ratings raised Kiniksa Pharmaceuticals International from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, May 6th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $60.86.

Kiniksa Pharmaceuticals International Trading Down 0.6%

Shares of KNSA opened at $53.34 on Wednesday. The firm has a market cap of $4.10 billion, a PE ratio of 59.27 and a beta of 0.17. The firm has a fifty day simple moving average of $48.98 and a two-hundred day simple moving average of $44.61. Kiniksa Pharmaceuticals International, plc has a 1-year low of $25.70 and a 1-year high of $59.87.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.09. The business had revenue of $214.27 million during the quarter, compared to analyst estimates of $206.11 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The company’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.11 EPS. As a group, research analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.24 EPS for the current fiscal year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.